Purpose: To report a case of painless posterior scleritis presenting as a choroidal nodule in a patient with history of a tumor being treated with pembrolizumab. Methods: A case and its findings were analyzed, and a relevant literature review was performed. Results: A 20-year-old woman with a history of ependymoma presented with painless blurred vision in the right eye after being started on pembrolizumab for a tumor recurrence. Fundoscopy showed a solitary amelanotic choroidal lesion with surrounding subretinal fluid in the affected eye. Ultrasonography showed moderate internal reflectivity and fluid in Tenon capsule consistent with nodular posterior scleritis. After a course of systemic steroids and discontinuation of the pembrolizumab, the choroidal lesion completely resolved. Conclusions: Clinicians should be aware of posterior scleritis as an ocular complication of this class of medications.
FortesBHLiouHDalvinLA.Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience. Br J Ophthalmol. 2021;105(9):1263-1271.
3.
UngCGragoudasE.Checkpoint inhibitor-induced sarcoid choroidal granulomas. Am J Ophthalmol Case Rep. 2020;18:100652.
4.
LiuXWangZZhaoC, et al. Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy. Thorac Cancer. 2020;11(3):810-818.
5.
YoungLFinniganSStreicherH, et al. Ocular adverse events in PD-1 and PD-L1 inhibitors. J Immunother Cancer. 2021;9(7):e002119.
6.
GerasimovaEVTabakovDVGerasimovaDAPopkovaTV.Activation markers on B and T cells and immune checkpoints in autoimmune rheumatic diseases. Int J Mol Sci. 2022;23(15):8656.
7.
NishimuraHNoseMHiaiHMinatoNHonjoT.Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11(2):141-151.
8.
WittDADonsonAMAmaniV, et al. Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: implications for PD-1-targeted therapy. Pediatr Blood Cancer. 2018;65:e26960.
9.
HaanenJCarbonnelFRobertC, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv119-iv142.
10.
KumarVChaudharyNGargMFloudasCSSoniPChandraAB.Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol. 2017;8:49.
11.
de VelascoGBermasBChoueiriTK. Autoimmune arthropathy and uveitis as complications of programmed death 1 inhibitor treatment. Arthritis Rheumatol. 2016;68(2):556-557.
12.
Gonzalez-GonzalezLAMolina-PratNDoctorPTauberJSainz de la MazaMFosterCS.Clinical features and presentation of posterior scleritis: a report of 31 cases. Ocul Immunol Inflamm. 2014;22(3):203-207.
13.
McCluskeyPJWatsonPGLightmanSHaybittleJRestoriMBranleyM.Posterior scleritis: clinical features, systemic associations, and outcome in a large series of patients. Ophthalmology. 1999;106(12):2380-2386.
